ZB
BIO icon

Zions Bancorporation’s Bio-Rad Laboratories Class A BIO Stock Holding History

Zions Bancorporation’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$669 – 867
2024
Q3 		$669 Hold
2
– – ﹤0.01% 831
2024
Q2 		$546 Sell
2
-1
-33% -$291 ﹤0.01% 889
2024
Q1 		$1.04K Sell
3
-1
-25% -$329 ﹤0.01% 853
2023
Q4 		$1.29K Sell
4
-1
-20% -$313 ﹤0.01% 846
2023
Q3 		$1.79K Sell
5
-11
-69% -$4.24K ﹤0.01% 822
2023
Q2 		$6.07K Sell
16
-8
-33% -$3.26K ﹤0.01% 705
2023
Q1 		$11.5K Hold
24
– – ﹤0.01% 617
2022
Q4 		$10.1K Buy
24
+23
+2,300% +$9.28K ﹤0.01% 715
2022
Q3 		$0 Sell
1
-1
-50% -$499 ﹤0.01% 933
2022
Q2 		$1K Sell
2
-14
-88% -$7.29K ﹤0.01% 1007
2022
Q1 		$9K Buy
16
+11
+220% +$6.63K ﹤0.01% 832
2021
Q4 		$4K Buy
5
+1
+25% +$748 ﹤0.01% 860
2021
Q3 		$3K Sell
4
-1
-20% -$749 ﹤0.01% 877
2021
Q2 		$3K Sell
5
-1
-17% -$609 ﹤0.01% 872
2021
Q1 		$3K Buy
+6
New +$3.55K ﹤0.01% 846
2020
Q4 		– Sell
-10
Closed -$5K – 942
2020
Q3 		$5K Buy
+10
New +$5.07K ﹤0.01% 803

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Zions Bancorporation's BIO Position: Q4 2024 in Review

Zions Bancorporation sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2024, closing a stake of 2 shares — an estimated $669 sold.

Zions Bancorporation first reported a position in BIO in Q3 2020 and held it in 16 quarters. The position peaked at $11.5K in Q1 2023. 457 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

  • Zions Bancorporation reported no remaining Bio-Rad Laboratories Class A position as of Q4 2024 after selling out during the quarter.
  • Zions Bancorporation sold 2 Bio-Rad Laboratories Class A shares in Q4 2024, an estimated $669.
  • Zions Bancorporation first reported a position in Bio-Rad Laboratories Class A in Q3 2020 and held it in 16 quarters.
  • Zions Bancorporation's Bio-Rad Laboratories Class A position peaked at $11.5K in Q1 2023.
  • 457 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Zions Bancorporation's 13F filing for Q4 2024, filed 11 Feb 2025.